Rigaku and SPERA PHARMA initiate Strategic Partnership to Advanced Pharmaceutical Development

22-Apr-2025

Rigaku Corporation and SPERA PHARMA, Inc. have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise.

Left: Keitaro Iwaki, President & Representative Director, SPERA PHARMA Right: Jun Kawakami, President & CEO, Rigaku

SPERA PHARMA will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development.

Furthermore, the two companies are collaborating closely to advance research utilizing the XtaLAB Synergy-ED and to actively share information on the application methods and analytical technologies.

Through this partnership, Rigaku and SPERA PHARMA aim to provide robust support at the forefront of pharmaceutical development, playing pivotal roles in pioneering the future of medicine.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?